American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S33-S41 , September 2007

Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001

  • Norma S. Harris, PhD

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, GA
    • ,
  • Mary Glenn Fowler, MD

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, GA
    • ,
  • Stephanie L. Sansom, PhD

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, GA
    • ,
  • Nan Ruffo, BS

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, GA
    • Northrop Grumman Information Technology, CDC Information Technology Support, Atlanta, GA.
    • ,
  • Margaret A. Lampe, RN, MPH

      Affiliations

    • Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, GA

References 

  1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–1180
  2. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1–infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000). HIV Clin Trials. 2001;2:56–91
  3. Centers for Disease Control and Prevention. Recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep. 1995;44:1–14
  4. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR Morb Mortal Wkly Rep. 2001;50:63–85
  5. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR Morb Mortal Wkly Rep. 2006;55:1–16
  6. Cooper E, Diaz C, Pitt J, et al. Impact of ACTG 076: use of ZDV (ZDV) during pregnancy and changes in the rate of HIV vertical transmission. Conf Retroviruses Opportunistic Infect. 1996;3:57
  7. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis. 1999;180:99–105
  8. Harris NS, Thompson SJ, Ball RT, Hussey J, Sy F. Zidovudine and perinatal human immunodeficiency virus type 1 transmission: a population-based approach. Pediatrics. 2002;109:1–7
  9. Peters V, Liu K, Dominguez K, et al. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of disease. Pediatrics. 2003;111:1186–1191
  10. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and the prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2004;29:484–494
  11. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-ZDV combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083–2093
  12. Centers for Disease Control and Prevention. In: HIV/AIDS surveillance report. 2001;p. 1–4713
  13. Fleming PL, Lindegren ML, Byers RH, et al. Estimated number of perinatal HIV infections, United States, 2000. [abstract] In: XIV International AIDS Conference. 2002;Abstract TuPeC4773
  14. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 2004;48:1–31
  15. Centers for Disease Control and Prevention. In: HIV/AIDS surveillance report. 2005;p. 1–4615
  16. Wade NA, Zielinski MA, Butsashvili M, et al. Decline in perinatal HIV transmission in New York State (1997-2000). J Acquir Immune Defic Syndr. 2004;36:1075–1082
  17. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. April 7. 2005;Last accessed: July 25, 2005. Available at: http://aidsinfo.nih.gov/guidelines/.
  18. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1–infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. In: 2005;p. 1–16February 24
  19. Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076: the changing pattern of ZDV use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants: Women and Infants Transmission Study Group. J Infect Dis. 1996;174:1207–1211
  20. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of ZDV therapy on transmission in rural and urban counties. JAMA. 1996;275:1483–1488
  21. Fiscus SA, Adimora AA, Funk ML, et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. Pediatr Infect Dis J. 2002;21:664–668
  22. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of ZDV and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials group protocol 185. J Infect Dis. 1999;179:567–575
  23. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189–198
  24. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened ZDV regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1: Perinatal HIV Prevention Trial (Thailand) investigators. N Engl J Med. 2000;343:982–991
  25. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard ZDV to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217–228
  26. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between ZDV prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA. 1998;280:55–60
  27. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic: United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329–332
  28. Davis SF, Byers RH, Lindegren ML, Caldwell MB, Karon JM, Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA. 1995;274:952–955
  29. Wortley PM, Lindegren ML, Fleming PL. Successful implementation of perinatal HIV prevention guidelines: a multistate surveillance evaluation. MMWR Recomm Rep. 2001;50:17–28

 Reprints not available from the authors.

 Supported by the Centers for Disease Control and Prevention Program announcement 0005.

 The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

PII: S0002-9378(07)00479-6

doi: 10.1016/j.ajog.2007.03.081

American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S33-S41 , September 2007

Article Tools